If you are a scientist performing cell therapy research using hematopoietic stem and progenitor cell (HSPC) sources, you know how important it is to start with high-quality materials with a large starting yield of CD34+ cells.
In this talk, Saba Aslam (Product Manager, Primary Cells) and Dr. Annie Bargsten (Field Application Scientist, Primary Cells) will introduce STEMCELL Technologies’ mobilized leukopaks and new products that support full workflows that include cell isolation, CD34+ cell expansion, differentiation, genome editing, and analysis. This webinar will also cover sources of CD34+ cells, different mobilizing agents, and detailed methods for processing mobilized leukopaks to isolate CD34+ cells.
Key Topics Include:
- An overview of CD34+ cells, their tissue sources, and applications
- A technical overview of mobilizing agents
- Different sources of CD34+ cells, including cord blood, bone marrow, and peripheral blood
- How to process a mobilized leukopak for CD34+ isolation
- Downstream workflow products for isolation, expansion, differentiation, genome editing, and analysis
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Presenters
Product Manager
Primary and Cultured Cells
STEMCELL Technologies
Saba Aslam holds a BSc in Biochemistry from McMaster University and an MSc in Biomedical Engineering from the University of Calgary, with a focus on stem cell research, tissue engineering, and regenerative medicine. With over 7 years of experience in the biotechnology industry and academia, she specializes in product development and cell research. She currently serves as the Product Manager for Primary Cells at STEMCELL Technologies.
Field Application Scientist
Primary and Cultured Cells
STEMCELL Technologies
Annie Bargsten has medical school training from Capital Medical University and a PhD in Cell and Molecular Biology from Colorado State University, where she focused on RNA decay in Myotonic Dystrophy. With over 12 years of experience in academia and the biotech industry, she has worked on bench science, including RNA decay and CAR-T cell therapy, as well as in technical support and field application roles. She currently serves as a Field Application Scientist for Primary Cells at STEMCELL Technologies.
Production Partner
STEMCELL Technologies Inc.
STEMCELL Technologies provides specialized cell culture media, cell isolation products, and reagents for your cell therapy and drug discovery research. Our ethically sourced human primary cell portfolio includes products from peripheral blood, cord blood, and bone marrow.
Additional Content From STEMCELL Technologies Inc.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
In Vivo panCAR™ Therapy Using Circular RNA for the Treatment of Autoimmune Disease
Learn how in vivo panCAR™ therapy, based on circular RNA and lipid nanoparticles, enables transient CAR expression and B cell depletion in preclinical models of autoimmune disease.
Enhance Your Tissue Processing Efficiency with the STEMprep™ Tissue Dissociator
Join Drs. Amanda Durkin and Grace Poon on October 2 as they explore how the STEMprep™ Tissue Dissociator System can simplify tissue processing and boost the efficiency of your biological research.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.
Related Content
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join us to learn how in-depth in vivo phenotyping using patient-relevant models can improve preclinical decision-making.
Detecting Early Synaptic Failure in Prion Disease Using Organoid Models
Join our webinar to see how early synaptic dysfunction can be captured with long-term organoid electrophysiology using Mesh MEA.